SELB Lots Of Technical Levels To Look At
NASDAQ:SELB filled that gap down from its data miss a few weeks back and now testing a pretty consistent level of previous support/resistance.
"Selecta and IGAN Biosciences entered into a research license and option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A protease for the treatment of IgA Nephropathy. We then saw the company and AskBio receive FDA Rare Pediatric Disease Designation for their gene therapy for methylmalonic Acidemia; several key milestones in a very short time span...Director Timothy Springer remains bullish on the company. He picked up another 3.6 million shares from October 21-23 at prices ranging from $2.4994 to $2.7147. Springer has been buying up shares for weeks. This latest round brings his position size to over 11 million shares in the company so far."
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
"Selecta and IGAN Biosciences entered into a research license and option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A protease for the treatment of IgA Nephropathy. We then saw the company and AskBio receive FDA Rare Pediatric Disease Designation for their gene therapy for methylmalonic Acidemia; several key milestones in a very short time span...Director Timothy Springer remains bullish on the company. He picked up another 3.6 million shares from October 21-23 at prices ranging from $2.4994 to $2.7147. Springer has been buying up shares for weeks. This latest round brings his position size to over 11 million shares in the company so far."
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.